https://markets.businessinsider.com/stocks/soltf-stock
Sosei Group Stock Price | SOLTF Stock Quote, News, and History | Markets Insider
The latest Sosei Group stock prices, stock quotes, news, and SOLTF history to help you invest and trade smarter.
news and historygroup stocksoseiprice
https://www.fiercebiotech.com/biotech/abbvie-gives-sosei-starring-role-neurological-drug-discovery-plans-paying-40m-and
AbbVie pays Sosei $40M to form neurological drug discovery pact
Aug 2, 2022 - AbbVie is paying $40 million and committing up to $1.2 billion to expand its relationship with the GPCR specialist into neurological diseases.
drug discoveryabbviepayssoseiform
https://www.prnewswire.com/news-releases/sosei-heptares-operational-highlights-and-consolidated-results-for-the-second-quarter-and-first-half-2021-301354006.html
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First...
/PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the...
operational highlights
https://www.biopharmadive.com/news/boehringer-ingelheim-sosei-schizophrenia-deal-gpr52/709858/
Boehringer, Sosei Heptares team up in schizophrenia drug deal | BioPharma Dive
Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple...
team upboehringersosei
https://www.globenewswire.com/fr/news-release/2024/03/21/2849872/0/en/Sosei-Heptares-Regains-Full-Ownership-from-GSK-of-HTL0027477-a-Clinic-ready-First-in-Class-Oral-GPR35-Agonist-for-Inflammatory-Bowel-Disease.html
Sosei Heptares Regains Full Ownership from GSK of
GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesReturn of rights...
full ownershipsoseiregainsgsk
https://www.sosei.it/
Home - sosei.it
sosei